Intellia Therapeutics
Forecast impact
Track in portfolio
Price chart
Description
Company and Business Model
Intellia Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR technology. Its core products include NTLA-2001, aimed at treating transthyretin amyloidosis, and NTLA-2002 for treating hereditary angioedema. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. Intellia is positioned as a niche player in the biotech industry.
Investment Profile
The investment profile of Intellia Therapeutics is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue generation. The company currently does not offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon to assess the development of its pipeline.
Fundamental metrics (experimental) Updated: 2026-07-26
- EPS (TTM) — earnings per share for the last 12 months, $
- -3.54
- Revenue QoQ — quarter-over-quarter revenue growth
- -34.6%
- EPS surprise
- 12.0%
- 20d volatility
- 3.8%
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-11 | Hold | Sell | Weak fundamentals and negative momentum signal high risk. |
| 2026-06-19 | Sell | Hold | Strong momentum but fundamentals show significant weakness. |
| 2026-06-11 | Hold | Sell | scenario_deterioration |
| 2026-06-05 | Sell | Hold | Weak fundamentals offset by recent positive momentum. |
| 2026-05-28 | Hold | Sell | Weak fundamentals with recent positive momentum. |
| 2026-05-08 | — | Hold | Strong revenue growth, but negative EPS and high risk. |
| 2026-05-08 | Hold | Hold | Компания демонстрирует значительный рост выручки и положительную динамику на длительном горизонте, однако отрицательный EPS и высокая волатильность указывают на определенные риски. |
| 2026-04-28 | — | Hold | Компания демонстрирует высокую волатильность и негативные показатели по прибыли, однако рост выручки в последнем квартале может свидетельствовать о потенциале для восстановления. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-15 | Wolfe Research | Rating Downgraded | — → 9 | 13.04 |
| 2026-07-10 | Wedbush | Target Raised | 12 → 17 | 14.71 |
| 2026-06-15 | New Street | Update | — → 25 | 12.11 |
| 2026-05-13 | Bernstein | Target Raised | 13 → 17 | 13.99 |
| 2026-05-12 | Canaccord Genuity | Target Lowered | 58 → 49 | 14.42 |
| 2026-04-27 | Chardan Capital | Target Raised | 27 → 30 | 13.03 |
| 2026-04-27 | Leerink Partners | Target Raised | 29 → 35 | 13.215 |
| 2026-04-27 | Morgan Stanley | Target Raised | 11 → 15 | 14.075 |
| 2026-04-27 | Robert W. Baird | Target Raised | 7 → 13 | 13.9403 |
| 2026-01-28 | KeyBanc | Target Raised | — → 25 | 13.9461 |
| 2026-01-27 | Robert W. Baird | Target Raised | — → 7 | 14.395 |
| 2025-11-11 | Evercore ISI | Rating Downgraded | — → 8 | 9.73 |
| 2025-11-10 | Truist Financial | Target Lowered | 25 → 14 | 9.91 |
News Page 1 of 1
Nothing yet